This “Minimal residual disease - Pipeline Insight, 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Minimal residual disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The pathophysiology of Minimal Residual Disease involves the persistence of small numbers of cancer cells that survive after treatment due to mechanisms such as intrinsic resistance, altered cell signaling, and immune evasion. These residual cells may exist in protective niches, like the bone marrow or central nervous system, where they are shielded from chemotherapy. Additionally, genetic and epigenetic changes can enhance their survival, allowing them to remain dormant or proliferate slowly. Over time, these cells can acquire further mutations, leading to disease relapse. MRD serves as a key indicator of treatment resistance and a predictor of potential recurrence.
The diagnosis of MRD relies on highly sensitive molecular techniques to detect residual cancer cells that remain after treatment but are undetectable by traditional microscopic methods. Key diagnostic approaches include flow cytometry, which identifies abnormal cells based on surface markers; polymerase chain reaction (PCR), such as real-time quantitative PCR (RQ-PCR) and reverse transcription PCR (RT-PCR), which amplify specific DNA sequences to detect minimal cancer cell presence; and next-generation sequencing (NGS), which provides high sensitivity by analyzing genetic mutations unique to an individual’s tumor. MRD testing is typically performed on bone marrow aspirates or peripheral blood samples, with the choice of method depending on the cancer type and clinical context. These advanced techniques play a crucial role in assessing treatment response, predicting relapse risk, and guiding therapeutic decisions.
Therapies include high-dose chemotherapy, proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, CAR T-cell therapy, and bispecific antibodies. MRD status helps guide treatment adjustments, with ongoing clinical trials exploring its role as a surrogate marker for therapeutic success.
"Minimal residual disease- Pipeline Insight, 2026" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Minimal residual disease pipeline landscape is provided which includes the disease overview and Minimal residual disease treatment guidelines. The assessment part of the report embraces, in depth Minimal residual disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Minimal residual disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This product will be delivered within 2 business days.
Minimal residual disease: Understanding
Minimal residual disease: Overview
Minimal residual disease (MRD) refers to the small number of cancer cells that remain in the body after treatment, even when no visible signs or symptoms of cancer are present. These residual cells have the potential to become active, multiply, and eventually lead to disease relapse. MRD can persist because some cancer cells may not have responded fully to therapy, or they may have developed resistance to the treatment. Detecting and monitoring MRD is crucial, as it helps assess the effectiveness of treatment and guide further therapeutic decisions to prevent recurrence. MRD does not usually cause noticeable symptoms because the number of remaining cancer cells is very small. Unlike active cancer, MRD does not produce physical signs such as pain, fatigue, or weight loss. However, if MRD leads to disease relapse, symptoms may develop depending on the type of cancer, including weakness, abnormal blood counts, or organ dysfunction.The pathophysiology of Minimal Residual Disease involves the persistence of small numbers of cancer cells that survive after treatment due to mechanisms such as intrinsic resistance, altered cell signaling, and immune evasion. These residual cells may exist in protective niches, like the bone marrow or central nervous system, where they are shielded from chemotherapy. Additionally, genetic and epigenetic changes can enhance their survival, allowing them to remain dormant or proliferate slowly. Over time, these cells can acquire further mutations, leading to disease relapse. MRD serves as a key indicator of treatment resistance and a predictor of potential recurrence.
The diagnosis of MRD relies on highly sensitive molecular techniques to detect residual cancer cells that remain after treatment but are undetectable by traditional microscopic methods. Key diagnostic approaches include flow cytometry, which identifies abnormal cells based on surface markers; polymerase chain reaction (PCR), such as real-time quantitative PCR (RQ-PCR) and reverse transcription PCR (RT-PCR), which amplify specific DNA sequences to detect minimal cancer cell presence; and next-generation sequencing (NGS), which provides high sensitivity by analyzing genetic mutations unique to an individual’s tumor. MRD testing is typically performed on bone marrow aspirates or peripheral blood samples, with the choice of method depending on the cancer type and clinical context. These advanced techniques play a crucial role in assessing treatment response, predicting relapse risk, and guiding therapeutic decisions.
Therapies include high-dose chemotherapy, proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, CAR T-cell therapy, and bispecific antibodies. MRD status helps guide treatment adjustments, with ongoing clinical trials exploring its role as a surrogate marker for therapeutic success.
"Minimal residual disease- Pipeline Insight, 2026" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Minimal residual disease pipeline landscape is provided which includes the disease overview and Minimal residual disease treatment guidelines. The assessment part of the report embraces, in depth Minimal residual disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Minimal residual disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Minimal residual disease R&D. The therapies under development are focused on novel approaches to treat/improve Minimal residual disease.Minimal residual disease Emerging Drugs Chapters
This segment of the Minimal residual disease report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.Minimal residual disease Emerging Drugs
- AMB-066: AmMax Bio
Minimal residual disease: Therapeutic Assessment
This segment of the report provides insights about the different Minimal residual disease drugs segregated based on following parameters that define the scope of the report, such as:Major Players in Minimal residual disease
- There are approx. 5+ key companies which are developing the therapies for Minimal residual disease. The companies which have their Minimal residual disease drug candidates in the most advanced stage, i.e. Phase II include, AmMax Bio.
Phases
The report covers around 5+ products under different phases of clinical development like:
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Minimal residual disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Molecule Type
Products have been categorized under various Molecule types such as:
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.Minimal residual disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Minimal residual disease therapeutic drugs key players involved in developing key drugs.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Minimal residual disease drugs.Minimal residual disease Report Insights
- Minimal residual disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Minimal residual disease Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Minimal residual disease drugs?
- How many Minimal residual disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Minimal residual disease?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Minimal residual disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Minimal residual disease and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Genentech
- AmMax Bio
- Precigen Inc
Key Products
- Glofitamab
- AMB-066
- PRGN-3006
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive SummaryMinimal residual disease- Analytical PerspectiveMinimal residual disease Key CompaniesMinimal residual disease Key ProductsMinimal residual disease- Unmet NeedsMinimal residual disease- Market Drivers and BarriersMinimal residual disease- Future Perspectives and ConclusionMinimal residual disease Analyst ViewsMinimal residual disease Key CompaniesAppendix
Minimal residual disease: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Drug Name: Company Name
Mid Stage Products (Phase II)
AMB-066: AmMax Bio
Early Stage Products (Phase I
Drug Name: Company Name
Preclinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Genentech
- AmMax Bio
- Precigen Inc
